Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated...

Full description

Saved in:
Bibliographic Details
Published in:Cell Cycle
Main Authors: Kawaguchi, Kei, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Eckardt, Mark A., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2018
Subjects:
Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914727/
https://ncbi.nlm.nih.gov/pubmed/29187018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1405195
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items